Wire · opportunities
Revolution's pancreatic cancer drug wins speedy FDA approval
26 August 2026 · By Derek Watson · Wire by Fusion42
Published
26 August 2026
Topic
opportunities
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 26 August 2026 · Fusion42 review
Revolution's pancreatic cancer drug, Daraxonrasib, has received speedy FDA approval, marking a significant regulatory milestone for cancer treatment.
This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
Your oncology biotech now faces faster regulatory paths for strategic drug launches. Speedy FDA approvals create a new norm where timely clinical evidence can open market doors more quickly.
◆ Coverage
48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026
- How the FDA Approval of Daraxonrasib Might Fuel Future Pancreatic Cancer Researchonclive.com · 16 October 2026
- Revolution's Rasonque Gets Broad Pancreatic Cancer Recommendation in Europegenomeweb.com · 15 October 2026
- Q&A: Daraxonrasib's Impact on Pancreatic Cancer Research & Patient Carephysiciansweekly.com · 5 October 2026
- Experimental pancreatic cancer drug offers new hope in major trialabc7.com · 4 October 2026
- Daraxonrasib for Pancreatic Cancermassgeneralbrigham.org · 2 October 2026
- Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Canceronclive.com · 29 September 2026
- Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?theglobeandmail.com · 17 September 2026
- FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAConclive.com · 15 September 2026
- Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech ...app.dealroom.co · 11 September 2026
- FDA Approval of Daraxonrasib in Pancreatic Canceronclive.com · 11 September 2026
- FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancerascopost.com · 10 September 2026
- A Breakthrough Pancreatic Drug is also Showing Results in Treating Lung Cancermix93.com · 8 September 2026
- Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution ...simplywall.st · 7 September 2026
- Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancermedpagetoday.com · 3 September 2026
- Pancreatic cancer drug may hold promise for lung cancer as well, early study suggestsabcnews.com · 3 September 2026
- New pancreatic cancer drug gives South Portland man hope for longer lifepressherald.com · 3 September 2026
- Karmanos now offers FDA-approved Daraxonrasib (Rasonque) for metastatic pancreatic cancertoday.wayne.edu · 1 September 2026
- Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancermclaren.org · 31 August 2026
- Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancersg.finance.yahoo.com · 31 August 2026
- 'Miracle drug' used by Sasse receives FDA approvalpressreader.com · 30 August 2026
- Patients with the deadliest cancer finally have something that workssg.finance.yahoo.com · 29 August 2026
- 'I'm still here:' South Florida patients see early promising results from new pancreatic cancer pillsun-sentinel.com · 29 August 2026
- FDA approves first RAS-targeting drug for pancreatic cancerdrugdiscoverynews.com · 28 August 2026
- Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion ...currently.att.yahoo.com · 28 August 2026
- FDA approves pancreatic cancer pill as Tyler patient sees results in similar clinical trialkltv.com · 28 August 2026
- Stage 4 Maine cancer patient says new FDA-approved pill is buying him timewgme.com · 28 August 2026
- Revolution Medicines (RVMD) Wins FDA Approval For Metastatic Pancreatic Cancer Drugsimplywall.st · 28 August 2026
- FDA approves breakthrough pancreatic cancer drug Rasonquefoxnews.com · 28 August 2026
- FDA approves Revolution Medicines' first in class targeted therapy for metastatic pancreatic cancerpmlive.com · 27 August 2026
- Rep. Sewell Celebrates the FDA Approval of a New Drug for Pancreatic Cancersewell.house.gov · 27 August 2026
- FDA approves landmark pancreatic cancer drug that's shown to improve survivalabcnews.com · 27 August 2026
- FDA Approves Revolution-ary New Drug for Pancreatic Cancercancerhealth.com · 27 August 2026
- FDA Approves Daraxonrasib: First-in-Class RAS Inhibitor for Metastatic Pancreatic Canceroncodaily.com · 27 August 2026
- FDA approves Rasonque for pancreatic cancer: When it's available and costyahoo.com · 27 August 2026
- How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?cancernetwork.com · 27 August 2026
- Pancreatic Cancer Drug Receives FDA Approvalkffhealthnews.org · 27 August 2026
- FDA approves pancreatic cancer drug that extends patients' liveswashingtonpost.com · 27 August 2026
- FDA Approves New Pancreatic Cancer Drug After Stunning Trial Resultsyahoo.com · 27 August 2026
- FDA approves breakthrough drug daraxonrasib to treat pancreatic cancerbbc.com · 27 August 2026
- Revolution's lifesaving pancreatic cancer drug wins speedy FDA approvalwtvbam.com · 27 August 2026
- FDA approves life-extending pancreatic cancer drug Rasonqueusatoday.com · 27 August 2026
- Revolution Medicines gets FDA nod for targeted pancreatic cancer drugdetroitnews.com · 26 August 2026
- FDA Approves RAS Inhibitor Daraxonrasib for Pancreatic Cancermedscape.com · 26 August 2026
- FDA approves new pancreatic cancer drug shown to extend survivalspectrumlocalnews.com · 26 August 2026
- FDA Approval of Daraxonrasib: A New Era for Pancreatic Cancer Treatmentjhoponline.com · 26 August 2026
- FDA approves 'game-changing' pancreatic cancer drugnbcnews.com · 26 August 2026
- Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAConclive.com · 26 August 2026
- Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drugajmc.com · 26 August 2026
- FDA approves breakthrough drug to treat advanced pancreatic cancerabcnews.com · 26 August 2026
- FDA OKs new pancreatic cancer drug trialed at Dana-Farberwcvb.com · 26 August 2026
- Daraxonrasib Gains FDA Approval for Pancreatic Canceroncologynewscentral.com · 26 August 2026
- Revolution Medicines gets FDA nod for targeted pancreatic cancer drugcnbc.com · 26 August 2026
- 'Grand Slam' Pancreatic Cancer Drug Wins FDA Approvalmedpagetoday.com · 26 August 2026
- Revolution Medicines gets FDA nod for targeted pancreatic cancer drugreuters.com · 26 August 2026
- FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancerhcplive.com · 26 August 2026
- Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.barrons.com · 26 August 2026
- FDA approves pancreatic cancer drug that nearly doubles survivalbeckersoncology.com · 26 August 2026
- FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinomaonclive.com · 26 August 2026
- FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancercancernetwork.com · 26 August 2026
- FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancerfda.gov · 26 August 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvalpancreatic-cancercancer-treatmentoncologydrug-approval